Expression data from durvalumab, oleclumab and combo-treated xenograft NSCLC tumors

Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations do not respond to anti-PD-1 (L1) as well as tumors without an EGFR mutation. We showed in a xenograft mouse model of EGFR-mutated NSCLC that, neither durvalumab nor oleclumab alone inhibited tumor growth compared to the isotype control. In contrast, the combination of both antibodies significantly inhibited tumor growth and increased gene expressions that corresponded to inflammation and T cell function in tumors treated. We used microarrays to study gene expressions that corresponded to enhanced immune response in antibody-treated mice. Tumor-bearing mice were treated with durvalumab, oleclumab or combination of both antibodies, together with tumor antigen-specific T cells. Total RNA was extracted from tumors and converted to biotin-labeled cRNA, which was then fragmented and hybridized on Affymetrix GeneChip.